Expert Opin Drug Saf:3岁以下儿童靶控输注丙泊酚的安全性和有效性:一项回顾性观察研究

2018-10-31 李华宇 “罂粟花”微信号

靶控输注丙泊酚用于麻醉是有效的,且围手术期未发生与丙泊酚相关的严重不良事件。

背景与目的

虽然丙泊酚在儿童中的需求量逐渐增加,但对3岁以下儿童使用丙泊酚进行麻醉诱导和维持在韩国尚未获得批准。本研究可为增加其使用范围提供临床依据。

方  法

我们回顾了2013年9月至2016年12月期间接受手术的3岁以下患者的医疗记录。根据患者生命体征评估丙泊酚的安全性,并根据患者脑电双频指数(BIS)评估丙泊酚实验室结果和有效性。记录不良事件的发生情况。

结  果

在倾向评分匹配后对109例使用丙泊酚麻醉的患者(丙泊酚组)和109例使用吸入麻醉的患者(吸入麻醉组)进行比较。两组患者术中收缩压(P<0.001)和心率(P=0.03)下降的比例存在差异,但舒张压(P=0.238)和平均动脉压(P=0.175)差异无统计学意义。术后两组患者生命体征和出现不良事件的比例差异无统计学意义。

结  论

靶控输注丙泊酚用于麻醉是有效的,且围手术期未发生与丙泊酚相关的严重不良事件。

原始出处:

Kang P, Jang YE, Kim EH, et al. Safety and efficacy of propofol anesthesia for pediatric target-controlled infusion in children below 3 years of age: a retrospective observational study.[J]. Expert Opin Drug Saf. 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2066644, encodeId=501d206664494, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Mar 30 21:15:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862321, encodeId=56cb1862321c3, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Apr 16 23:15:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688972, encodeId=3d6216889e2c3, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Sun Mar 24 06:15:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727701, encodeId=4cb01e27701b6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 08 18:15:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351191, encodeId=168a35119158, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Nov 01 18:56:16 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2066644, encodeId=501d206664494, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Mar 30 21:15:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862321, encodeId=56cb1862321c3, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Apr 16 23:15:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688972, encodeId=3d6216889e2c3, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Sun Mar 24 06:15:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727701, encodeId=4cb01e27701b6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 08 18:15:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351191, encodeId=168a35119158, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Nov 01 18:56:16 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-04-16 wangbingxhy
  3. [GetPortalCommentsPageByObjectIdResponse(id=2066644, encodeId=501d206664494, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Mar 30 21:15:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862321, encodeId=56cb1862321c3, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Apr 16 23:15:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688972, encodeId=3d6216889e2c3, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Sun Mar 24 06:15:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727701, encodeId=4cb01e27701b6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 08 18:15:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351191, encodeId=168a35119158, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Nov 01 18:56:16 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2066644, encodeId=501d206664494, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Mar 30 21:15:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862321, encodeId=56cb1862321c3, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Apr 16 23:15:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688972, encodeId=3d6216889e2c3, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Sun Mar 24 06:15:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727701, encodeId=4cb01e27701b6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 08 18:15:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351191, encodeId=168a35119158, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Nov 01 18:56:16 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-05-08 feather89
  5. [GetPortalCommentsPageByObjectIdResponse(id=2066644, encodeId=501d206664494, content=<a href='/topic/show?id=1d3d45e090e' target=_blank style='color:#2F92EE;'>#安全性和有效性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45709, encryptionId=1d3d45e090e, topicName=安全性和有效性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/E33DC517C2EC449E463E3D01D81745BA/100, createdBy=75e12500157, createdName=ms1756883563247400, createdTime=Sat Mar 30 21:15:00 CST 2019, time=2019-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862321, encodeId=56cb1862321c3, content=<a href='/topic/show?id=1f0e626267' target=_blank style='color:#2F92EE;'>#Drug#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6262, encryptionId=1f0e626267, topicName=Drug)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=baf586, createdName=wangbingxhy, createdTime=Tue Apr 16 23:15:00 CST 2019, time=2019-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688972, encodeId=3d6216889e2c3, content=<a href='/topic/show?id=b65f90588b8' target=_blank style='color:#2F92EE;'>#观察研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90588, encryptionId=b65f90588b8, topicName=观察研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4fa28698173, createdName=ms7258648636991762, createdTime=Sun Mar 24 06:15:00 CST 2019, time=2019-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1727701, encodeId=4cb01e27701b6, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 08 18:15:00 CST 2019, time=2019-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=351191, encodeId=168a35119158, content=谢谢分享学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4o2XVpJ6449yqDsjibydI5HnJ8MibGxNn4HZiaZib0bdfibbwoz3KQrIyN9AGxq36ZlZRNicYlPfOOWMtwgsajY6mGNFiaPclFdowjD0/0, createdBy=97bd1338592, createdName=清风拂面, createdTime=Thu Nov 01 18:56:16 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 清风拂面

    谢谢分享学习

    0

相关资讯

2017 SIED意见书:非麻醉医生胃肠内镜检查应用丙泊酚

2017年9月,意大利消化内镜学会(SIED)发布了关于非麻醉医生胃肠内镜检查应用丙泊酚的意见书。胃肠内镜检查过程中非麻醉医生应用丙泊酚镇静,通常被认为是安全的操作程序,但仍然存在争论。本文主要总结了丙泊酚的应用管理和患者监测的相关内容,为胃肠内镜检查过程中非麻醉医生应用丙泊酚提供指导建议。

Anesth Analg:丙泊酚-瑞芬太尼靶控输注下患者的催眠深度对标准化强直刺激时瞳孔对光反射的影响:交叉随机试验研究

瞳孔测量法用来测量瞳孔直径变化对伤害性刺激的反应。这种技术已被用于监测镇痛和伤害感受之间的平衡。在全身麻醉下,瞳孔扩张的幅度与给予阿片类药物的量有关。这项研究的目的是确定是否在恒定的阿片类药物输注速率下,采用双频指数(BIS)评估催眠深度对瞳孔反应的影响。

丙泊酚:麻醉药里的“王者”

有诺贝尔奖风向标之称的美国拉斯克奖,将临床医学奖颁给了丙泊酚(又名异丙酚)的研发者约翰·格伦(John B. Glen)。作为麻醉医生的我,自是欢欣鼓舞。在我每天的临床麻醉工作里,我都使用到这种药物。丙泊酚呈现为乳白色液体,常被麻醉医生称为“牛奶”。这种药物到底有什么魔力,能让拉斯克奖都为之倾心?在临床麻醉中,它又有什么地位呢?

Br J Anaesth:与七氟醚全身麻醉相比,丙泊酚可降低老年人神经认知功能恢复延迟的发生率

全身麻醉药的选择可能会影响术后认知结局。本研究旨在比较基于丙泊酚和基于七氟醚的全身麻醉对重大癌症手术后老年人早期神经认知功能恢复延迟的潜在影响。

BMC Cancer:丙泊酚和七氟醚对乳腺癌手术患者肿瘤细胞、自然杀伤细胞和细胞毒性T淋巴细胞功能的 影响:体外研究

虽然基础科学研究已经表明丙泊酚在癌症手术中可能优于挥发性药物,但在NK细胞和CTL细胞计数和包括乳腺癌细胞在内的细胞凋亡率方面,丙泊酚在乳腺癌手术麻醉过程中的作用并不优于七氟醚。

手术用多少麻醉剂?或将由病人自主决定

未来或允许手术患者自主控制手术中的清醒程度和术后苏醒过来的速度。